Formulation Development
Bayer Announces First Patients Enrolled in Global Phase 3 Studies for Investigational Oral FXIa Inhibitor Asundexian
Bayer recently announced the first patients have been enrolled in the initial trials for its OCEANIC clinical trial program, designed to explore the use of…
Nectin Therapeutics to Collaborate With Merck on Clinical Trial of Anti-PVR Antibody in Combination with KEYTRUDA in Patients With Locally Advanced & Metastatic Solid Tumors
Nectin Therapeutics Ltd. recently announced it has entered into a clinical trial collaboration agreement with Merck. Under this collaboration, Nectin will evaluate the safety, tolerability, and antitumor activity of its novel….
Indaptus Therapeutics Activates Morristown Medical Center as Trial Site in INDP-D101, Its Ongoing Phase 1 Open Label Clinical Trial of Decoy20 in Patients With Advanced Solid Tumors
Indaptus Therapeutics, Inc. recently announced the addition of Morristown Medical Center, part of the Atlantic Health System, as a new clinical trial site for INDP-D101,…
Endogena Therapeutics Receives Fast Track Designation for EA-2353 for the Treatment of Retinitis Pigmentosa
Endogena Therapeutics Inc. recently announced the US FDA has designated the investigation of EA-2353 for the treatment of retinitis pigmentosa (RP) as a Fast Track…
Immutep Reaches Enrolment Target for INSIGHT-003 Trial in 1st Line NSCLC
Immutep Limited recently announced the investigator-initiated INSIGHT-003 trial has reached its enrolment target of 20 patients with 1L NSCLC. INSIGHT-003 is the first trial evaluating…
BD Introduces High-Throughput Single-Cell Multiomics Platform to Expand Scope of Scientific Discovery
BD (Becton, Dickinson and Company) recently announced a new instrument for single-cell multiomics analysis that will enable scientists to run high-throughput studies without sacrificing sample…
Revive Therapeutics Enters Research Collaboration Agreement With PharmaTher for Development of MDMA Transdermal Patch
Revive Therapeutics Ltd. recently announced it has entered into a research collaboration agreement with PharmaTher Holdings Ltd. to evaluate the delivery of 3,4-Methylenedioxymethamphetamine (MDMA) using PharmaTher’s novel microneedle….
First Wave BioPharma Announces First Patient Screened for Phase 2 SPAN Adrulipase Trial in Cystic Fibrosis
First Wave BioPharma, Inc. recently announced the first patient was screened for the Phase 2 SPAN clinical trial investigating an enhanced enteric microgranule delivery formulation…
Purple Biotech Expands Pipeline of First-in-Class Therapeutics With Acquisition of Immunorizon & Its Portfolio of Tri-Specific Antibodies for the Treatment of Cancer
Purple Biotech Ltd. recently announced it has entered into an agreement for the acquisition of Immunorizon Ltd., a private company developing potential multi-specific T and NK cell engager oncology therapies that….
Artelo Biosciences Completes Enrollment of the Phase 1b Stage of its CAReS Clinical Trial Evaluating ART27.13 for the Treatment of Cancer-Related Anorexia & Weight Loss
Artelo Biosciences, Inc. recently announced enrollment in the final cohort of the Phase 1b stage of its Cancer Appetite Recovery Study (CAReS) is now complete.…
Frontera Therapeutics Doses First Patient in a Clinical Trial of Gene Therapy for the Treatment of Wet AMD
Frontera Therapeutics recently announced it has dosed the first patient in a clinical trial of its innovative gene therapy product, FT-003, at the Ophthalmology Hospital…
Seqens Group Opens Flagship Pharmaceutical R&D Center in Greater Boston
Seqens Group recently announced it has opened Seqens Boston R&D Center, a state-of-the-art, 15,000-sq-ft R&D center in Devens, MA. Serving as one of the company’s…
Gerresheimer Presents its New Clinical Trial Kit to Accelerate Drug Development
Gerresheimer presents its new Clinical Trial Kit at Pharmapack in Paris. This kit consists of sterile Gx RTF vials in nest and tub or tray…
Akoya Biosciences to Present First-of-its-Kind Spatial Multiomics Dataset
Akoya Biosciences, Inc. recently announced it will present results from a novel same-section, spatial multiomic study at the Advances in Genome Biology and Technology (AGBT)…
Aptamer Group Partners With BaseCure Therapeutics to Develop New Targeted Gene Therapies
Aptamer Group plc recently announced a new partnership with BaseCure Therapeutics for the development of Optimer-targeted gene therapies. The ability to precisely target gene therapies,…
WHITEPAPER - Case Study-Improving Bioavailability Using PBPK Modeling & Parallel Formulation Screening
A team of bioavailability experts at Catalent used the in-house bioavailability enhancement platform, OptiForm® Solution Suite, to optimize and develop….
WHITEPAPER - Infographic-Zydis® Orally Disintegrating Tablet (ODT) vs. Standard Tablets (ST)
Catalent’s proprietary Zydis® ODT platform is backed by a large number of clinical studies. This infographic provides a high level summary of studies comparing Zydis ODT against traditional oral tablets…..
First Wave BioPharma Announces Initiation of Phase 2 Trial Investigating Enhanced Adrulipase Formulation in Exocrine Pancreatic Insufficiency in Patients With Cystic Fibrosis
First Wave BioPharma, Inc. recently announced it will initiate its planned Phase 2 clinical trial of an enhanced enteric microgranule delivery formulation for adrulipase for…
X-Chem & Kymera Expand Existing Partnership
X-Chem recently announced the expansion of its collaboration with Kymera Therapeutics, Inc. With the expanded agreement, X-Chem will serve as the primary provider of DNA-encoded….
Start-Up Innovation at Pharmapack 2023
Pharmapack Europe 2023 returns to its traditional February timing for the first time since the start of the pandemic and provides the industry with a vital early window into many of tomorrow’s technologies that improve patient experience, adherence, and delivery…..
